Autologous stem cell transplantation in tandem with Anti-CD30 CAR T-cell infusion in relapsed/refractory CD30⁺ lymphoma.

ABSTRACT:

Background

Long-term outcome is unfavourable for relapsed/refractory (r/r) lymphoma patients who are resistant to salvage chemotherapy, even after subsequent autologous stem-cell transplantation (ASCT). Although anti-CD30 chimeric antigen receptor (CAR30) T-cell therapy induces high response rates in these patients, the duration of response is relatively limited.

Methods

This open-label, single-center and single-arm pilot study investigated the safety and efficacy of ASCT in tandem with CAR30 T-cell infusion in r/r CD30⁺ lymphoma. The primary endpoint was safety and key secondary endpoint was overall response rate, overall survival, progression-free survival, and duration of response.

Results

Five classical Hodgkin lymphoma (cHL) patients and 1 anaplastic l

SUBMITTER: Zhang P 

PROVIDER: S-EPMC9578248 | biostudies-literature | 2022 Oct

REPOSITORIES: biostudies-literature